Publications by authors named "Eleni Dalabira"
Article Synopsis
- This text indicates that there is a correction to a previously published article identified by the DOI number 10.1371/journal.pone.0162866.
- The correction may involve updates or clarifications regarding the study's findings, methodology, or conclusions.
- Readers should refer to the corrected version for accurate information related to the research presented in the original article.
Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicity with the underlying genetic composition, particularly in genes encoding for protein factors and enzymes involved in drug metabolism and transport. In several European populations, particularly in countries with lower income, information related to the prevalence of pharmacogenomic biomarkers is incomplete or lacking. Here, we have implemented the microattribution approach to assess the pharmacogenomic biomarkers allelic spectrum in 18 European populations, mostly from developing European countries, by analyzing 1,931 pharmacogenomics biomarkers in 231 genes.
View Article and Find Full Text PDFBackground/aims: Pharmacogenomics aims to rationalize drug use by minimizing drug toxicity and/or by increasing drug efficacy. A large number of genomic markers have been correlated with variable drug responses and severity of adverse drug reactions. Although a number of these drugs bear pharmacogenomic information in their labels--approved by regulatory agencies--and comprehensive drug/gene lists exist online, information related to the respective pharmacogenomic biomarkers is currently missing from such lists.
View Article and Find Full Text PDF